A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family
CARD11 is a lymphocyte-specific scaffold molecule required for proper activation of B- and T-cells in response to antigen. Germline gain-of-function (GOF) mutations in the CARD11 gene cause a unique B cell lymphoproliferative disorder known as B cell Expansion with NF-κB and T cell Anergy (BENTA). I...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.02944/full |
id |
doaj-27da10c6f70a47b49f5c81ba79866af4 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marylin Desjardins Marylin Desjardins Swadhinya Arjunaraja Jeffrey R. Stinson Batsukh Dorjbal Janani Sundaresan Julie Niemela Mark Raffeld Helen F. Matthews Angela Wang Angela Wang Pamela Angelus Pamela Angelus Helen C. Su Bruce D. Mazer Bruce D. Mazer Andrew L. Snow |
spellingShingle |
Marylin Desjardins Marylin Desjardins Swadhinya Arjunaraja Jeffrey R. Stinson Batsukh Dorjbal Janani Sundaresan Julie Niemela Mark Raffeld Helen F. Matthews Angela Wang Angela Wang Pamela Angelus Pamela Angelus Helen C. Su Bruce D. Mazer Bruce D. Mazer Andrew L. Snow A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family Frontiers in Immunology CARD11 BENTA Atopy B cell lymphocytosis primary immumunodeficiencies |
author_facet |
Marylin Desjardins Marylin Desjardins Swadhinya Arjunaraja Jeffrey R. Stinson Batsukh Dorjbal Janani Sundaresan Julie Niemela Mark Raffeld Helen F. Matthews Angela Wang Angela Wang Pamela Angelus Pamela Angelus Helen C. Su Bruce D. Mazer Bruce D. Mazer Andrew L. Snow |
author_sort |
Marylin Desjardins |
title |
A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family |
title_short |
A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family |
title_full |
A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family |
title_fullStr |
A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family |
title_full_unstemmed |
A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family |
title_sort |
unique heterozygous card11 mutation combines pathogenic features of both gain- and loss-of-function patients in a four-generation family |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2018-12-01 |
description |
CARD11 is a lymphocyte-specific scaffold molecule required for proper activation of B- and T-cells in response to antigen. Germline gain-of-function (GOF) mutations in the CARD11 gene cause a unique B cell lymphoproliferative disorder known as B cell Expansion with NF-κB and T cell Anergy (BENTA). In contrast, patients carrying loss-of-function (LOF), dominant negative (DN) CARD11 mutations present with severe atopic disease. Interestingly, both GOF and DN CARD11 variants cause primary immunodeficiency, with recurrent bacterial and viral infections, likely resulting from impaired adaptive immune responses. This report describes a unique four-generation family harboring a novel heterozygous germline indel mutation in CARD11 (c.701-713delinsT), leading to one altered amino acid and a deletion of 4 others (p.His234_Lys238delinsLeu). Strikingly, affected members exhibit both moderate B cell lymphocytosis and atopic dermatitis/allergies. Ectopic expression of this CARD11 variant stimulated constitutive NF-κB activity in T cell lines, similar to other BENTA patient mutations. However, unlike other GOF mutants, this variant significantly impeded the ability of wild-type CARD11 to induce NF-κB activation following antigen receptor ligation. Patient lymphocytes display marked intrinsic defects in B cell differentiation and reduced T cell responsiveness in vitro. Collectively, these data imply that a single heterozygous CARD11 mutation can convey both GOF and DN signaling effects, manifesting in a blended BENTA phenotype with atopic features. Our findings further emphasize the importance of balanced CARD11 signaling for normal immune responses. |
topic |
CARD11 BENTA Atopy B cell lymphocytosis primary immumunodeficiencies |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2018.02944/full |
work_keys_str_mv |
AT marylindesjardins auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT marylindesjardins auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT swadhinyaarjunaraja auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT jeffreyrstinson auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT batsukhdorjbal auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT jananisundaresan auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT julieniemela auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT markraffeld auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT helenfmatthews auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT angelawang auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT angelawang auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT pamelaangelus auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT pamelaangelus auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT helencsu auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT brucedmazer auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT brucedmazer auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT andrewlsnow auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT marylindesjardins uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT marylindesjardins uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT swadhinyaarjunaraja uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT jeffreyrstinson uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT batsukhdorjbal uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT jananisundaresan uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT julieniemela uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT markraffeld uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT helenfmatthews uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT angelawang uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT angelawang uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT pamelaangelus uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT pamelaangelus uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT helencsu uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT brucedmazer uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT brucedmazer uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily AT andrewlsnow uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily |
_version_ |
1725825564604891136 |
spelling |
doaj-27da10c6f70a47b49f5c81ba79866af42020-11-24T22:05:36ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-12-01910.3389/fimmu.2018.02944414125A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation FamilyMarylin Desjardins0Marylin Desjardins1Swadhinya Arjunaraja2Jeffrey R. Stinson3Batsukh Dorjbal4Janani Sundaresan5Julie Niemela6Mark Raffeld7Helen F. Matthews8Angela Wang9Angela Wang10Pamela Angelus11Pamela Angelus12Helen C. Su13Bruce D. Mazer14Bruce D. Mazer15Andrew L. Snow16Division of Allergy and Immunology, Department of Paediatrics, McGill University Health Centre, Montreal, QC, CanadaMeakins-Christie Laboratories of the Research Institute of the McGill University Health Centre, Montreal, QC, CanadaDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of Health Sciences, Bethesda, MD, United StatesDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of Health Sciences, Bethesda, MD, United StatesDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of Health Sciences, Bethesda, MD, United StatesDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of Health Sciences, Bethesda, MD, United StatesDepartment of Laboratory Medicine, NIH Clinical Center, Bethesda, MD, United StatesLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesLaboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United StatesLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United StatesClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., National Cancer Institute at Frederick, Frederick, MD, United StatesLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United StatesClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., National Cancer Institute at Frederick, Frederick, MD, United StatesLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United StatesDivision of Allergy and Immunology, Department of Paediatrics, McGill University Health Centre, Montreal, QC, CanadaMeakins-Christie Laboratories of the Research Institute of the McGill University Health Centre, Montreal, QC, CanadaDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of Health Sciences, Bethesda, MD, United StatesCARD11 is a lymphocyte-specific scaffold molecule required for proper activation of B- and T-cells in response to antigen. Germline gain-of-function (GOF) mutations in the CARD11 gene cause a unique B cell lymphoproliferative disorder known as B cell Expansion with NF-κB and T cell Anergy (BENTA). In contrast, patients carrying loss-of-function (LOF), dominant negative (DN) CARD11 mutations present with severe atopic disease. Interestingly, both GOF and DN CARD11 variants cause primary immunodeficiency, with recurrent bacterial and viral infections, likely resulting from impaired adaptive immune responses. This report describes a unique four-generation family harboring a novel heterozygous germline indel mutation in CARD11 (c.701-713delinsT), leading to one altered amino acid and a deletion of 4 others (p.His234_Lys238delinsLeu). Strikingly, affected members exhibit both moderate B cell lymphocytosis and atopic dermatitis/allergies. Ectopic expression of this CARD11 variant stimulated constitutive NF-κB activity in T cell lines, similar to other BENTA patient mutations. However, unlike other GOF mutants, this variant significantly impeded the ability of wild-type CARD11 to induce NF-κB activation following antigen receptor ligation. Patient lymphocytes display marked intrinsic defects in B cell differentiation and reduced T cell responsiveness in vitro. Collectively, these data imply that a single heterozygous CARD11 mutation can convey both GOF and DN signaling effects, manifesting in a blended BENTA phenotype with atopic features. Our findings further emphasize the importance of balanced CARD11 signaling for normal immune responses.https://www.frontiersin.org/article/10.3389/fimmu.2018.02944/fullCARD11BENTAAtopyB cell lymphocytosisprimary immumunodeficiencies |